FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076256886> ?p ?o ?g. }

• W2076256886 endingPage "461" @default.
• W2076256886 startingPage "454" @default.
• W2076256886 abstract "To evaluate the efficacy of high-titer intravenous respiratory syncytial virus immune globulin (RSVIG) in the treatment of children at high risk for severe RSV infection who were hospitalized with proven RSV.Infants and young children younger than 2 years with bronchopulmonary dysplasia, chronic lung disease, congenital heart disease, or prematurity (<32 weeks' gestational age), hospitalized with a history of lower respiratory tract infection (LRI) of less than 4 days, were enrolled in this study. Patients were randomized in a blinded fashion to receive either 1500 mg/kg RSVIG or placebo in equal volumes. They were evaluated daily for safety and respiratory scores and for RSV nasal shedding.One hundred seven high-risk children were randomized--54 in the RSVIG group and 53 in the placebo group. Of these children, 51 in each group were considered evaluable. Children with pulmonary disease, congenital heart disease, or prematurity were equally distributed between the two treatment groups. However, two important differences were found in baseline variables between the two groups: there were more patients in the placebo group who had histories of previous LRI and there was a trend toward more severe disease at study entry in the RSVIG group. This was manifested by a higher entry respiratory score in the RSVIG group than in the placebo group (3.4 +/- 0.2 vs 3.1 +/- .01). A higher proportion of children in the RSVIG group (47%) than in the placebo group (28%) required intensive care at entry and mechanical ventilation at study entry (31% RSVIG-treated vs 18% placebo-treated patients). No significant difference was found between groups in the mean unadjusted duration of hospitalization (RSVIG group, 9.10 +/- 1.18 days; control group, 8.17 +/- 1.08 days). When the mean was adjusted for entry respiratory score, likewise, no difference was observed between each group (8.41 +/- 0.97 vs 8.89 +/- .99 days). The lack of efficacy observed in the study primary endpoint was observed in all diagnostic groups. No differences between the RSVIG and placebo groups were observed in the following secondary endpoints: duration of intensive care unit stay, duration of intensive care unit stay for RSV, mechanical ventilation, or supplemental oxygen. No significant differences in adverse events were reported in the RSVIG group (16 children) when compared with the control group (10 children).RSVIG treatment was safe but not efficacious in the treatment of children with bronchopulmonary dysplasia, congenital heart disease, or premature gestation who were hospitalized with RSV LRI." @default.
• W2076256886 created "2016-06-24" @default.
• W2076256886 creator A5000433934 @default.
• W2076256886 creator A5014098236 @default.
• W2076256886 creator A5026194032 @default.
• W2076256886 creator A5029291810 @default.
• W2076256886 creator A5030766632 @default.
• W2076256886 creator A5064141604 @default.
• W2076256886 creator A5066490756 @default.
• W2076256886 creator A5072190625 @default.
• W2076256886 creator A5072808846 @default.
• W2076256886 creator A5084178893 @default.
• W2076256886 creator A5086524484 @default.
• W2076256886 creator A5090484188 @default.
• W2076256886 date "1997-03-01" @default.
• W2076256886 modified "2023-10-01" @default.
• W2076256886 title "Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections" @default.
• W2076256886 cites W1492538632 @default.
• W2076256886 cites W1606213737 @default.
• W2076256886 cites W1824800369 @default.
• W2076256886 cites W1897316425 @default.
• W2076256886 cites W1898933481 @default.
• W2076256886 cites W1929167949 @default.
• W2076256886 cites W1929856540 @default.
• W2076256886 cites W1966099212 @default.
• W2076256886 cites W1987856010 @default.
• W2076256886 cites W2002985673 @default.
• W2076256886 cites W2005955822 @default.
• W2076256886 cites W2017489436 @default.
• W2076256886 cites W2019108630 @default.
• W2076256886 cites W2025040902 @default.
• W2076256886 cites W2036877259 @default.
• W2076256886 cites W2043913576 @default.
• W2076256886 cites W2064297954 @default.
• W2076256886 cites W2064704406 @default.
• W2076256886 cites W2071136162 @default.
• W2076256886 cites W2089767471 @default.
• W2076256886 cites W2168044318 @default.
• W2076256886 cites W2316897460 @default.
• W2076256886 cites W2318832328 @default.
• W2076256886 cites W2319815586 @default.
• W2076256886 cites W2323052125 @default.
• W2076256886 cites W2328116798 @default.
• W2076256886 cites W4245170709 @default.
• W2076256886 doi "https://doi.org/10.1542/peds.99.3.454" @default.
• W2076256886 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9041304" @default.
• W2076256886 hasPublicationYear "1997" @default.
• W2076256886 type Work @default.
• W2076256886 sameAs 2076256886 @default.
• W2076256886 citedByCount "149" @default.
• W2076256886 countsByYear W20762568862012 @default.
• W2076256886 countsByYear W20762568862013 @default.
• W2076256886 countsByYear W20762568862014 @default.
• W2076256886 countsByYear W20762568862015 @default.
• W2076256886 countsByYear W20762568862017 @default.
• W2076256886 countsByYear W20762568862018 @default.
• W2076256886 countsByYear W20762568862019 @default.
• W2076256886 countsByYear W20762568862020 @default.
• W2076256886 countsByYear W20762568862021 @default.
• W2076256886 countsByYear W20762568862022 @default.
• W2076256886 countsByYear W20762568862023 @default.
• W2076256886 crossrefType "journal-article" @default.
• W2076256886 hasAuthorship W2076256886A5000433934 @default.
• W2076256886 hasAuthorship W2076256886A5014098236 @default.
• W2076256886 hasAuthorship W2076256886A5026194032 @default.
• W2076256886 hasAuthorship W2076256886A5029291810 @default.
• W2076256886 hasAuthorship W2076256886A5030766632 @default.
• W2076256886 hasAuthorship W2076256886A5064141604 @default.
• W2076256886 hasAuthorship W2076256886A5066490756 @default.
• W2076256886 hasAuthorship W2076256886A5072190625 @default.
• W2076256886 hasAuthorship W2076256886A5072808846 @default.
• W2076256886 hasAuthorship W2076256886A5084178893 @default.
• W2076256886 hasAuthorship W2076256886A5086524484 @default.
• W2076256886 hasAuthorship W2076256886A5090484188 @default.
• W2076256886 hasConcept C126322002 @default.
• W2076256886 hasConcept C142724271 @default.
• W2076256886 hasConcept C187212893 @default.
• W2076256886 hasConcept C203014093 @default.
• W2076256886 hasConcept C204787440 @default.
• W2076256886 hasConcept C2522874641 @default.
• W2076256886 hasConcept C27081682 @default.
• W2076256886 hasConcept C2776012195 @default.
• W2076256886 hasConcept C2776178081 @default.
• W2076256886 hasConcept C2776399701 @default.
• W2076256886 hasConcept C2777714996 @default.
• W2076256886 hasConcept C2778376644 @default.
• W2076256886 hasConcept C2778721537 @default.
• W2076256886 hasConcept C2778821649 @default.
• W2076256886 hasConcept C2779234561 @default.
• W2076256886 hasConcept C2780727368 @default.
• W2076256886 hasConcept C2780813555 @default.
• W2076256886 hasConcept C2909511158 @default.
• W2076256886 hasConcept C534529494 @default.
• W2076256886 hasConcept C54355233 @default.
• W2076256886 hasConcept C71924100 @default.
• W2076256886 hasConcept C86803240 @default.
• W2076256886 hasConceptScore W2076256886C126322002 @default.
• W2076256886 hasConceptScore W2076256886C142724271 @default.

• next